TY - JOUR
T1 - Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma
T2 - Impact of dose on treatment outcomes
AU - Rades, Dirk
AU - Sehmisch, Lena
AU - Huttenlocher, Stefan
AU - Blank, Oliver
AU - Hornung, Dagmar
AU - TerheydeN, Patrick
AU - Gliemroth, Jan
AU - Schild, Steven E.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Background/Aim: To compare different doses of stereotactic radiosurgery (SRS) for 1-3 newly-diagnosed cerebral metastases from melanoma. Patients and Methods: Fifty-four patients were assigned to dose groups of 20 Gy (N=36) and 21-22.5 Gy (N=18). Variables additionally analyzed were age, gender, Karnofsky Performance Score (KPS), lactate dehydrogenase (LDH) before SRS, number of cerebral lesions, extracranial lesions, time from melanoma diagnosis to SRS. Results: The 12-month local control was 72% after 20 Gy and 100% after 21-22.5 Gy (p=0.020). Freedom from new cerebral metastases (p=0.13) and survival (p=0.13) showed no association with SRS dose. On multivariate analyses, improved local control showed significant associations with SRS doses of 21-22.5 Gy (p=0.007) and normal lactate dehydrogenase levels (p=0.018). Improved survival was associated with normal LDH levels (p=0.006) and KPS 90-100 (p=0.046). Conclusion: SRS doses of 21-22.5 Gy resulted in better local control than 20 Gy. Freedom from new brain metastases and survival were not significantly different.
AB - Background/Aim: To compare different doses of stereotactic radiosurgery (SRS) for 1-3 newly-diagnosed cerebral metastases from melanoma. Patients and Methods: Fifty-four patients were assigned to dose groups of 20 Gy (N=36) and 21-22.5 Gy (N=18). Variables additionally analyzed were age, gender, Karnofsky Performance Score (KPS), lactate dehydrogenase (LDH) before SRS, number of cerebral lesions, extracranial lesions, time from melanoma diagnosis to SRS. Results: The 12-month local control was 72% after 20 Gy and 100% after 21-22.5 Gy (p=0.020). Freedom from new cerebral metastases (p=0.13) and survival (p=0.13) showed no association with SRS dose. On multivariate analyses, improved local control showed significant associations with SRS doses of 21-22.5 Gy (p=0.007) and normal lactate dehydrogenase levels (p=0.018). Improved survival was associated with normal LDH levels (p=0.006) and KPS 90-100 (p=0.046). Conclusion: SRS doses of 21-22.5 Gy resulted in better local control than 20 Gy. Freedom from new brain metastases and survival were not significantly different.
UR - http://www.scopus.com/inward/record.url?scp=84908679374&partnerID=8YFLogxK
M3 - Journal articles
C2 - 25202094
AN - SCOPUS:84908679374
SN - 0250-7005
VL - 34
SP - 5079
EP - 5082
JO - Anticancer Research
JF - Anticancer Research
IS - 9
ER -